| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PTGR1 |
| Uniprot No | Q14914 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-329aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSEFMVRTK TWTLKKHFVG YPTNSDFELK TAELPPLKNG EVLLEALFLT VDPYMRVAAK RLKEGDTMMG QQVAKVVESK NVALPKGTIV LASPGWTTHS ISDGKDLEKL LTEWPDTIPL SLALGTVGMP GLTAYFGLLE ICGVKGGETV MVNAAAGAVG SVVGQIAKLK GCKVVGAVGS DEKVAYLQKL GFDVVFNYKT VESLEETLKK ASPDGYDCYF DNVGGEFSNT VIGQMKKFGR IAICGAISTY NRTGPLPPGP PPEIVIYQEL RMEAFVVYRW QGDARQKALK DLLKWVLEGK IQYKEYIIEG FENMPAAFMG MLKGDNLGKT IVKA |
| 预测分子量 | 39 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于PTGR1重组蛋白的参考文献(虚构示例，仅供格式参考)：
1. **"Heterologous expression and functional characterization of human PTGR1 in Escherichia coli"**
*Authors: Zhang L, et al.*
*摘要*：本研究成功构建了人源PTGR1重组蛋白的大肠杆菌表达系统，通过亲和层析纯化获得高纯度蛋白，并证实其具有催化PGE2转化为13.14-dihydro-15-keto PGE2的活性。
2. **"Structural insights into PTGR1-mediated prostaglandin metabolism by X-ray crystallography"**
*Authors: Tanaka K, et al.*
*摘要*：报道了重组PTGR1蛋白的晶体结构解析，揭示了其底物结合域的关键氨基酸残基，为靶向PTGR1的药物设计提供了结构基础。
3. **"PTGR1 regulates oxidative stress in hepatocellular carcinoma via NADPH oxidase interaction"**
*Authors: Wang Y, et al.*
*摘要*：通过体外重组PTGR1蛋白实验，证明其与NADPH氧化酶的相互作用可调控肝癌细胞内的ROS水平，影响肿瘤增殖和转移。
(注：以上文献为模拟内容，实际研究中请通过PubMed或Web of Science检索真实文献。)
PTGR1 (Prostaglandin Reductase 1), also known as 15-hydroxyprostaglandin dehydrogenase [NAD+] (15-PGDH), is a key enzyme involved in the metabolism of bioactive lipid mediators, particularly prostaglandins. It catalyzes the NADPH-dependent reduction of 15-keto prostaglandins to their corresponding 13.14-dihydro-15-keto metabolites, effectively regulating the bioavailability and signaling activity of these molecules. Prostaglandins, such as PGE2 and PGF2α, play critical roles in inflammation, tissue repair, and cancer progression, making PTGR1 a pivotal modulator of these physiological and pathological processes.
Structurally, PTGR1 belongs to the short-chain dehydrogenase/reductase (SDR) superfamily, characterized by a conserved Rossmann-fold domain for cofactor binding. The enzyme is widely expressed in mammalian tissues, with high levels observed in the liver, kidney, and intestine. Its activity is tightly linked to cellular redox balance due to its dependence on NADPH as a cofactor.
Research has implicated PTGR1 in various diseases. In cancer, it exhibits dual roles depending on context: while its prostaglandin-degrading function may suppress tumor growth in certain cancers (e.g., colorectal cancer), it has also been associated with promoting metastasis in hepatocellular carcinoma by modulating lipid peroxidation pathways. Additionally, PTGR1 interacts with the PPARγ signaling axis, influencing metabolic and inflammatory responses.
Recombinant PTGR1 protein, typically produced in E. coli or mammalian expression systems, serves as a vital tool for studying prostaglandin metabolism, enzyme kinetics, and drug discovery. Purification methods often incorporate affinity tags (e.g., His-tag) for efficient isolation. Current studies utilize recombinant PTGR1 to explore its therapeutic potential in inflammatory disorders, fibrotic diseases, and cancer, as well as its interplay with oxidative stress pathways involving Nrf2 signaling.
×
